Phase 1Completed
A Pharmacokinetics Study of Intravenous Ascorbic Acid
A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers
- Sponsor
- McGuff Pharmaceuticals, Inc. (Industry)
- Enrolment
- 8 enrolled
- Conditions
- Pharmacokinetics
- Interventions
- Ascor L 500® (Ascorbic Acid Injection, USP)
- Ages
- adults
- Registry
- NCT02534753
Full record on ClinicalTrials.gov
From the registry
This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic Acid.
Primary outcomes
- Concentration of Ascorbic Acid (µM) in plasma
History
Last registry update
Study completion
Primary completion
Started
Registered